Hanbio was founded in 2010 and is a high-tech enterprise focused on gene technology research and application transformation, located in Zhangjiang High tech Park. Hanheng has always been committed to the research and production of gene vectors, and our core competitive products include lentiviruses, adenoviruses, and adeno-associated viruses; At the same time, we focus on hot topics, including autophagy flow research tools, virus vector based crispr gene editing tools, non coding RNA, and luciferase experiments. Our independently developed autophagy LC3 double labeled adenovirus is a gold medal research tool in the field of autophagy.
So far, there have been over 8000 publications of viral products, including over 1000 academic journals published by Hanbio Autophagy Virus Products, with an average of IF> 6.5, including journals such as Cell, Cancer Cell, Nature Medicine, Autophagy, Circulation, etc.
In the future, we will focus more on the application of core gene technology in clinical transformation.
Hanbio, Better Gene Technology.
2010
Established in Shanghai Zhangjiang High tech Park
2013
Take the lead in developing self phagocytic double label virus products
Three out of every four autophagic adenoviruses come from Hanhio
2016
The product has been cited multiple times by CELL journals
Virus products are exported to North America and the Middle East
2017
Becoming a high-tech enterprise in Shanghai
2019
Introducing a new production management system, reducing customer complaint rate to less than 1%
Continuously expanding market share, increasing by 50% month on month
2025
Goal: Collaborate with domestic clinical institutions to apply for and implement preclinical and clinical research projects for gene therapy
Listing 1-2 gene therapy AAV drugs with independent intellectual property rights
联系我们
返回顶部
